Tharimmune, Inc. is a biotechnology company focused on developing innovative therapies to address autoimmune diseases and other immune system-related disorders. The company leverages advanced technologies and scientific research to create targeted treatments that aim to modulate immune responses, improving patient outcomes and quality of life. Tharimmune's pipeline includes several therapeutic candidates in various stages of development, reflecting its commitment to advancing the understanding and treatment of complex immunological conditions. Through collaborations and a dedicated approach to research and development, Tharimmune aspires to make significant contributions to the field of immunotherapy. Read More
Aprea Therapeutics, Inc. (Nasdaq: APRE) is a clinical-stage biopharmaceutical company pioneering a new era in precision oncology. By combining deep genetic insight with targeted molecular design, Aprea is advancing therapies that exploit cancer-specific vulnerabilities — aiming to outsmart tumor biology while preserving healthy tissue and improving patient quality of life.
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Shares of Tharimmune are surging in Monday afternoon trading. The company last week announced promising simulation results for its lead clinical asset, TH104.
Shares of Tharimmune are surging Thursday afternoon. The company on Wednesday announced positive results from a simulation analysis of its lead clinical asset, TH104.
